XVIVO Heart Transplant Study in Clinical Practice (NCT07556588) | Clinical Trial Compass
RecruitingNot Applicable
XVIVO Heart Transplant Study in Clinical Practice
Belgium20 participantsStarted 2026-04-15
Plain-language summary
HOPE for All is a clinical investigation to support the use of hypothermic oxygenated perfusion (HOPE) using a revised XVIVO Heart Assist Transport System in a real- world setting.
The trial will investigate the application of HOPE in a broad population of Donation after Brain Death (DBD) and Donation after Circulatory Death (DCD) donor hearts transplanted to any listed adult patient.
The hypothesis is that the use of HOPE is safe and feasible for any adult patient awaiting a heart transplantation.
Primary objective is to evaluate patient survival in the real world setting after heart transplantation, where HOPE using the revised XVIVO Heart Assist Transport System is used for donor heart preservation.
Secondary objective(s) are to evaluate patient outcomes and graft function post-transplant.
HOPE for All is a prospective, single-armed single-centre proof-of-consept trial.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Age ≥18 years
✓. Signed informed consent form
✓. Accepted or listed for heart transplantation
✓. Accepted as a heart donor by the transplant team based on current standard of care criteria
✓. DBD or DCD Maastricht category III or euthanasia donors
Exclusion criteria
✕. Not able to understand the information provided during the informed consent procedure
✕. Combined organ transplantation candidates
✕. Functional warm ischemia time (FWIT) \> 30 minutes (DCD).
✕. Donor cardiac arrest does not occur within 120 minutes from Withdrawal of life sustaining therapy (DCD)
✕. Deviations from Donor end of life treatment protocol as defined by local standard operating procedures